Individualized medicine for epilepsy - Based on genetic information

Epilepsy and Seizure

Volumn 3, Issue 1, 2010, Pages 163-191

  Yoshida, Shuichi ^a,b   Saruwatari, Junji ^a,c   Chen, Lei ^a,d   Liu, Fang ^a,e   Iwasa, Hiroto ^a,f   Sugawara, Takayuki ^a,g   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d SICHUAN UNIVERSITY   (China)

^e CHINA MEDICAL UNIVERSITY   (China)

^f Aomori Prefectural Center for Mental Health and Welfare   (Japan)

^g Tohoku Chemical Co Ltd   (Japan)

Author keywords

Cytochrome P450; Drug Efflux transporter; Epilepsy gene; Epilepsy model animals; Genetic testing; Individualized medicine

Indexed keywords

ABC TRANSPORTER SUBFAMILY B; ANTICONVULSIVE AGENT; CALCIUM CHANNEL; CARBAMAZEPINE; CARRIER PROTEIN; CYTOCHROME P450; ION CHANNEL; PHENOBARBITAL; PROTEIN VARIANT; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL; ZONISAMIDE;

DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EPILEPSY; ETHNIC DIFFERENCE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HUMAN; MARKER GENE; MOLECULAR GENETICS; NONHUMAN; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; PHENOTYPE; PREDICTION; REVIEW; TREATMENT RESPONSE;

EID: 84886950130     PISSN: None     EISSN: 18825567     Source Type: Journal    
DOI: 10.3805/eands.3.163     Document Type: Review

References (133)

1. Berg AT. Epidemiologic aspects of epilepsy. In: The treatment of epilepsy (4th edition). Wyllie E (Ed.), Lippincott Williams & Wilkins, Philadelphia, USA, 2006, pp109-116.
2. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001; 42: 515-524.
3. Schmidt D, Löscher W. How effective is surgery to cure seizures in drug-resistant temporal lobe epilepsy? Epilepsy Res 2003; 56 (2-3): 85-89.
4. Kaneko S, Yoshida S, Kanai K, Yasui-Furukori N, Iwasa H. Development of individualized medicine for epilepsy based on genetic information. Expert Rev Clin Pharmacol 2008; 1(5): 661-681.
5. Saitsu H, Kato M, Mizuguchi T, Hamada K, Osaka H, Tohyama J, Uruno K, Kumada S, Nishiyama K, Nishimura A, Okada I, Yoshimura Y, Hirai S, Kumada T, Hayasaka K, Fukuda A, Ogata K, Matsumoto N. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat Genet 2008; 40(6): 782-788.
6. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428(6982): 486.
7. Ikeda H, Takahashi Y, Yamazaki E, Fujiwara T, Kaniwa N, Saito Y, Aihara M, Kashiwagi M, Muramatsu M. HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 2010; 51(2): 297-300
8. Wang JW, Kurahashi H, Ishii A, Kojima T, Ohfu M, Inoue T, Ogawa A, Yasumoto S, Oguni H, Kure S, Fujii T, Ito M, Okuno T, Shirasaka Y, Natsume J, Hasegawa A, Konagaya A, Kaneko S, Hirose S. Microchromosomal deletions involving SCN1A and adjacent genes in severe myoclonic epilepsy in infancy. Epilepsia 2008; 49(9): 1528-1534.
9. Meisler MH, Kearney JA. Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest 2005; 115(8): 2010-2017.
10. Singh NA, Westenskow P, Charlier C, Pappas C, Leslie J, Dillon J, Anderson VE, Sanguinetti MC, Leppert MF; BFNC Physician Consortium. KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions: expansion of the functional and mutation spectrum. Brain 2003; 126(Pt 12): 2726-2737.
11. Medina MT, Suzuki T, Alonso ME, Durón RM, Martínez-Juárez IE, Bailey JN, Bai D, Inoue Y, Yoshimura I, Kaneko S, Montoya MC, Ochoa A, Prado AJ, Tanaka M, Machado-Salas J, Fujimoto S, Ito M, Hamano S, Sugita K, Ueda Y, Osawa M, Oguni H, Rubio-Donnadieu F, Yamakawa K, Delgado-Escueta AV. Novel mutations in Myoclonin1/EFHC1 in sporadic and familial juvenile myoclonic epilepsy. Neurology 2008; 70(22 Pt 2): 2137-2144.
12. Yoshida S, Miyashita A, Kuwano R, Kojima T, Sasaki T, Zhu G, Kanai K, Fujita H, Hirose S, Kaneko S, The Epilepsy Genetic Study Group Japan. Genome-wide identification of febrile seizure and related epilepsy phenotype loci, Epilepsy & Seizure 2008; 1 (1): 30-39.
13. Kanai K, Hirose S, Oguni H, Fukuma G, Shirasaka Y, Miyajima T, Wada K, Iwasa H, Yasumoto S, Matsuo M, Ito M, Mitsudome A, Kaneko S. Effect of localization of missense mutations in SCN1A on epilepsy phenotype severity. Neurology 2004; 63(2): 329-334.
14. Kanai K, Yoshida S, Hirose S, Oguni H, Kuwabara S, Sawai S, Hiraga A, Fukuma G, Iwasa H, Kojima T, Kaneko S. Physicochemical property changes of amino acid residues that accompany missense mutations in SCN1A affect epilepsy phenotype severity. J Med Genet 2009; 46(10): 671-679.
15. Cavalleri GL, Weale ME, Shianna KV, Singh R, Lynch JM, Grinton B, Szoeke C, Murphy K, Kinirons P, O'Rourke D, Ge D, Depondt C, Claeys KG, Pandolfo M, Gumbs C, Walley N, McNamara J, Mulley JC, Linney KN, Sheffield LJ, Radtke RA, Tate SK, Chissoe SL, Gibson RA, Hosford D, Stanton A, Graves TD, Hanna MG, Eriksson K, Kantanen AM, Kalviainen R, O'Brien TJ, Sander JW, Duncan JS, Scheffer IE, Berkovic SF, Wood NW, Doherty CP, Delanty N, Sisodiya SM, Goldstein DB. Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurol 2007; 6(11): 970-980.
16. Lucarini N, Verroti A, Napolioni V, Bosco G, Curatolo P. Genetic polymorphisms and idiopathic generalized epilepsies. Pediatr Neurol 2007; 37: 157-164.
17. Heron SE, Scheffer IE, Berkovic SF, Dibbens LM, Mully JC. Channelopathies in idiopathic epilepsy. Neurotherapeutics 2007; 4: 295-304.
18. Dube CM, Brewster AL, Richichi C, Zha Q, Baram T. Fever, febrile seizures and epilepsy. TRENDS in Neurosci 2007; 30(10): 490-496.
19. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987; 413(1): 185-188.
20. Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 1997; 231(3): 123-126.
21. Rundfeldt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur J Pharmacol 1997; 336(2-3): 243-249.
22. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci Lett 2000; 282(1-2): 73-76.
23. Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 2001; 21(15): 5535-5545.
24. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000; 58(2): 253-262.
25. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anticonvulsant, enhances activation of KCNQ2/ Q3 potassium channels. Mol Pharmacol 2000; 58(3): 591-600.
26. Guerrini R, Parmeggiani L. Topiramate and its clinical applications in epilepsy. Expert Opin Pharmacother 2006; 7(6): 811-823.
27. Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 1989; 25(6): 582-593.
28. Suzuki S, Kawakami K, Nishimura S, Watanabe Y, Yagi K, Seino M, Miyamoto K. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992; 12(1): 21-27.
29. Kelly KM, Gross RA, Macdonald RL. Valproic acid selectively reduces the lowthreshold (T) calcium current in rat nodose neurons. Neurosci Lett 1990; 116(1-2): 233-238.
30. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271(10): 5768-5776.
31. Stefani A, Spadoni F, Bernardi G. Voltageactivated calcium channels: targets of antiepileptic drug therapy? Epilepsia 1997; 38 (9): 959-965.
32. Wang SJ, Tsai JJ, Gean PW. Lamotrigine inhibits depolarization-evoked Ca++ influx in dissociated amygdala neurons. Synapse 1998; 29(4): 355-362.
33. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the highvoltage-activated Ca(2+) current in pyramidal neurons of rat hippocampal slices. Neurosci Lett 2000; 306(1-2): 5-8.
34. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002; 43 (1): 9-18.
35. Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen G, Selak I, Matagne A, Klitgaard H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA-and glycine-gated currents. Br J Pharmacol 2002; 136(5): 659-672.
36. Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gammaaminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989; 25(3): 213-220.
37. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABAevoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997; 28(3): 167-179.
38. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995; 36(6): 612-626.
39. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004; 5(7): 553-564.
40. Hosford DA, Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997; 38(4): 408-414.
41. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000; 41(S1): 17-20.
42. Wallace RH, Marini C, Petrou S, Harkin LA, Bowser DN, Panchal RG, Williams DA, Sutherland GR, Mulley JC, Scheffer IE, Berkovic SF. Mutant GABA(A) receptor gamma-2-subunit in childhood absence epilepsy and febrile seizures. Nature Genet 2001; 28: 49-52.
43. Angehagen M, Ben-Menachem E, Shank R, Ronnback L, Hansson E. Topiramate modulation of kainite-induced calcium currents is inversely related to channel phosphorylation level. J Neurochem 2004; 88 (2): 320-325.
44. Coulter DA. Mossy fiber zinc and temporal lobe epilepsy: pathological association with altered “epileptic” gamma-aminobutyric acid A receptors in dentate granule cells. Epilepsia 2000; 41(S6): 96-99.
45. Skradski S, White HS. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 2000; 41(S1): 45-47.
46. Kleckner NW, Glazewski JC, Chen CC, Moscrip TD. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action. J Pharmacol Exp Ther 1999; 289(2): 886-894.
47. Harty TP, Rogawski MA. Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res 2000; 39(1): 47-55.
48. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27(5): 490-497.
49. Mizuno K, Okada M, Murakami T, Kamata A, Zhu G, Kawata Y, Wada K, Kaneko S. Effects of carbamazepine on acetylcholine release and metabolism. Epilepsy Res 2000; 40(2-3): 187-195.
50. Murakami T, Okada M, Kawata Y, Zhu G, Kamata A, Kaneko S. Determination of effects of antiepileptic drugs on SNAREsmediated hippocampal monoamine release using in vivo microdialysis. Br J Pharmacol 2001; 134(3): 507-520.
51. Okada M, Zhu G, Yoshida S, Kanai K, Hirose S, Kaneko S. Exocytosis mechanism as a new targeting site for mechanisms of action of antiepileptic drugs. Life Sci 2002; 72 (4-5): 465-473.
52. Kaneko S, Okada M, Mizuno K. Mechanisms of mood stabilizing effects of antiepileptic drugs: Differences between acute and chronic effects of antiepileptic drugs on monoaminergic and acetylcholinergic functions. Ann. Rep. Pharmacopsychiat Res Found 1995; 26: 107-117.
53. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29(3): 233-349.
54. Okada M, Yoshida S, Zhu G, Hirose S, Kaneko S. Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca(2+)-releasing systems. Neuroscience 2005; 134(1): 233-246.
55. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004; 101(26): 9861-9866.
56. Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adin J. Ion channels and epilepsy. Curr Pharm Des. 2005; 11(15): 1975-2003.
57. Kaneko S, Nau H. Mechanisms of action of valproate. In Clinical Pharmacology of Valproate (2nd edition). Kaneko S, Nau H (Ed), Life Science, Tokyo, Japan, 2006: 16-26.
58. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, Dulac O, Pons G. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356 (9242): 1638-1642.
59. Borgatti R, Zucca C, Cavallini A, Ferrario M, Panzeri C, Castaldo P, Soldovieri MV, Baschirotto C, Bresolin N, Dalla Bernardina B, Taglialatela M, Bassi MT. A novel mutation in KCNQ2 associated with BFNC, drug resistant epilepsy, and mental retardation. Neurology 2004; 63: 57-65.
60. Cossette P, Liu L, Brisebois K, Dong H, Lortie A, Vanasse M, Saint-Hilaire JM, Carmant L, Verner A, Lu WY, Wang YT, Rouleau GA. Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nature Genet 2002; 31: 184-189.
61. Baulac S, Huberfeld G, Gourfinkel-An I, Mitropoulou G, Beranger A, Prud'homme JF, Baulac M, Brice A, Bruzzone R, LeGuern E. First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma-2-subunit gene. Nature Genet 2001; 28: 46-48.
62. Harkin LA, Bowser DN, Dibbens LM, Singh R, Phillips F, Wallace RH, Richards MC, Williams DA, Mulley JC, Berkovic SF, Scheffer IE, Petrou S. Truncation of the GABA-A-receptor gamma-2 subunit in a family with generalized epilepsy with febrile seizures plus. Am J Hum Genet 2000; 70: 530-536.
63. Audenaert D, Schwartz E, Claeys KG, Claes L, Deprez L, Suls A, Van Dyck T, Lagae L, Van Broeckhoven C, Macdonald RL, De Jonghe P. A novel GABRG2 mutation associated with febrile seizures. Neurology 2000; 67: 687-690.
64. Hirose S, Okada M, Zhu G. Studies on the pathogeneses underlying epilepsy using model animals bearing abnormality identified in human epilepsy. Ann Rep Jpn Epi Res Found 2007; 18: 49-54.
65. Aridon P, Marini C, Di Resta C, Brilli E, De Fusco M, Politi F, Parrini E, Manfredi I, Pisano T, Pruna D, Curia G, Cianchetti C, Pasqualetti M, Becchetti A, Guerrini R, Casari G. Increased sensitivity of the neuronal nicotinic receptor alpha-2 subunit causes familial epilepsy with nocturnal wandering and ictal fear. Am J Hum Genet 2006; 79: 342-350.
66. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs car-bamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005; 102(15): 5507-5512.
67. Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepineresistant epilepsy. Br J Clin Pharmacol 2008; 66(2): 304-307.
68. Lucas PT, Meadows LS, Nicholls J, Ragsdale DS. An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin. Epilepsy Res 2005; 64 (3): 77-84.
69. Remy S, Urban BW, Elger CE, Beck H. Anticonvulsant pharmacology of voltagegated Na+ channels in hippocampal neurons of control and chronically epileptic rats. Eur J Neurosci 2003; 17 (12): 2648-2658.
70. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC; RegiSCAR Group. A marker for Stevens-Johnson syndrome…: ethnicity matters. Pharmacogenomics J 2006; 6(4): 265-268.
71. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7(6): 813-818.
72. Richens A. Clinical pharmacokinetics of gabapentin. In Chadwick D, ed. New trends in epilepsy management: the role of gabapentin. London, Royal Society of Medicine Services 1993; 41-46.
73. Pellock JM, Glauser TA, Bebin EM, Fountain NB, Ritter FJ, Coupez RM, Shields WD. Pharmacokinetic study of levetiracetam in children. Epilepsia 2001; 42(12): 1574-1579.
74. Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 2007; 46(4): 271-279.
75. Mamiya K, Hadama A, Yukawa E, Ieiri I, Otsubo K, Ninomiya H, Tashiro N, Higuchi S. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol 2000; 55(11-12): 821-825.
76. Goto S, Seo T, Murata T, Nakada N, Ueda N, Ishitsu T, Nakagawa K. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther Drug Monit 2007; 29(1): 118-121.
77. Ho PC, Abbott FS, Zanger UM, Chang TK. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J 2003; 3(6): 335-342.
78. Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001; 52(5): 547-553.
79. Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci 2006; 94(2): 261-271.
80. Andreasen AH, Brøsen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on CYP3A4. Epilepsia 2007; 48 (3): 490-496.
81. Okada Y, Seo T, Ishitsu T, Wanibuchi A, Hashimoto N, Higa Y, Nakagawa K. Population estimation regarding the effects of cytochrome P450 2C19 and 3A4 polymorphisms on zonisamide clearance. Ther Drug Monit 2008; 30(4): 540-543.
82. Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Takahashi T. A major influence of CYP2C19 genotype on the steadystate concentration of Ndesmethylclobazam. Brain Dev 2004; 26 (8): 530-534.
83. Seo T, Nagata R, Ishitsu T, Murata T, Takaishi C, Hori M, Nakagawa K. Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.. Pharmacogenetics 2008; 9(5): 527-537.
84. Hidaka M, Okumura M, Fujita K, Ogikubo T, Yamasaki K, Iwakiri T, Setoguchi N, Arimori K. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos 2005; 33(5): 644-648.
85. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62(1): 162-172.
86. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 2004; 19(2): 120-129.
87. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2009; 85(2): 155-163.
88. Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, Hee B, Garrett M, Kikkawa H, Lin CY, Eddy SM, Dostalik J, Mount J, Azuma J, Fujio Y, Jang IJ, Shin SG, Bleavins MR, Williams JA, Paulauskis JD, Wilner KD. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first-and thirdgeneration Japanese populations: Comparison With Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 2008; 84 (3): 347-361.
89. Yasui-Furukori N, Kaneda A, Iwashima K, Saito M, Nakagami T, Tsuchimine S, Kaneko S. Association between cytochrome P450 (CYP) 2C19 polymorphisms and harm avoidance in Japanese. Am J Med Genet B 2007; 144B: 724-727.
90. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Saito T, Parkinson A, Nakagawa K, Kamataki T. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. Xenobiotica 2005; 35(1): 69-83.
91. Kwan P. Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a clinical review. Epilepsia 2004; 45: 1141-1149.
92. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004; 63: S3-S8.
93. Shimomasuda M, Okada Y, Seo T, Goto S, Saruwatari J, Yoshida S, Kaneko S, Ishitsu T, Nakagawa K. Determination of the influence of cytochrome P450 polymorphisms on the pharmacokinetics of carbamazepine, Phenobarbital and zonisamaide in Japanese patients with epilepsy. The 43rd Congress of the Japan Epilepsy Society: Post Congress International Symposium on Pharmacogenomics in Epilepsy 2009; Abstract: P6.
94. Makeeva O, Stepanov V, Puzyrev V, Goldstein DB, Grosman I. Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes. Pharmacogenomics 2008; 9: 847-868.
95. Heller AJ, Chesterman P, Elwes RD, Crawford P, Chadwick D, Johnson AL, Reynolds EH. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58(1): 44-50.
96. de Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BG, Johnson AL, Reynolds EH. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347(9003): 709-713.
97. Nimaga K, Desplats D, Doumbo O, Farnarier G. Treatment with pentobarbital and monitoring of epileptic patients in rural Mali. Bull World Health Organ 2002; 80:532-537.
98. Wang WZ, Wu JZ, Ma GY, Dai XY, Yang B, Wang TP, Yuan CL, Hong Z, Bell GS, Prilipko L, de Boer HM, Sander JW. Efficacy assessment of phenobarbital in epilepsy: a large community-based intervention trial in rural China. Lancet Neurol 2006; 5(1): 46-52.
99. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002; 24(1): 91-103.
100. Baulac M. Introduction to zonisamide. Epilepsy Res. 2006; 68(2): S3-S9.
101. Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol 1998; 54(2): 177-183.
102. Eichelbaum M, Tomson T, Tybring G, Bertilsson L. Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokinet 1985; 10(1): 80-90.
103. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47(11): 1969-1979.
104. Kang P, Liao M, Wester MR, Leeder JS, Pearce RE, Correia MA. CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZCYP3A4 adduct and alteration of the enzyme kinetic profile. Drug Metab Dispos 2008; 6(3): 490-499.
105. Seo T, Nakada N, Ueda N, Hagiwara T, Hashimoto N, Nakagawa K. Effect of CYP3A5*3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy. Clin Pharmacol Ter 2006; 79: 509-510.
106. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27(4): 383-391.
107. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10(5): 373-388.
108. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12 (2): 121-132.
109. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, Wilkinson GR. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European-and African-American men and women. Pharmacogenetics 2003; 13(10): 595-606.
110. Ohmori S, Nakasa H, Asanome K, Kurose Y, Ishii I, Hosokawa M, Kitada M. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim Biophys Acta 1998; 1380 (3): 297-304.
111. Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 2004; 32(12): 1434-1445.
112. Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandström R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther 2008; 84(1):52-62.
113. Sisodiya SM, Lin W-R, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002; 125: 22-31.
114. Vogelgesang S, Kunert-Keil C, Cascorbi I, Mosyagin I, Schröder E, Runge U, Jedlitschky G, Kroemer HK, Oertel J, Gaab MR, Pahnke J, Walker LC, Warzok RW. Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy. Clin Neuropathol 2004; 23(5): 223-231.
115. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Losher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse Pglycoprotein. Neuropharmacology 2007; 52: 333-346.
116. Baltes S, Fedrowitz M, Tortós CL, Potschka H, Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007; 320(1): 331-343.
117. Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, Nakagawa K. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics. 2006; 7(4): 551-561.
118. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM. Association of multidrug re-sistance in epilepsy with a polymorphism in drug-transporter gene ABCB1. N Engl J Med 2003; 348(15): 1442-1448.
119. Zimprich F, Sunder-Plassmann R, Stogmann E, Gleiss A, Dal-Bianco A, Zimprich A, Plumer S, Baumgartner C, Mannhalter C. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 2004; 3(6): 1087-1089.
120. Simon C, Stieger B, Kullak-Ublick GA, Fried M, Mueller S, Fritschy JM, Wieser HG, Pauli-Magnus C. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand 2007; 115(4): 232-242.
121. Sills GJ, Kwan P, Butler E, de Lange EC, van den Berg DJ, Brodie MJ. Pglycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav 2002; 3(5): 427-432.
122. Seo T, Ishitsu T, Oniki K, Abe T, Shuto T, Nakagawa K. ABCC2 haplotype is not associated with drug-resistant epilepsy. J Pharm Pharmacol. 2008; 60: 1-6.
123. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6(8): 591-602.
124. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 26(315): 525-528.
125. Sisodita SM, Goldstein DB. Drug resistance in epilepsy: More twists in the tale. Epilepsia 2007; 48(12): 2369-2370.
126. Awasthi S, Sharma R, Singhal SS, Zimniak P, Awasthi YC. RLIP76, a novel transporter catalyzing ATP-dependent efflux of xenobiotics. Drug Metab Dispos 2002; 30(12): 1300-1310.
127. Awasthi S, Hallene KL, Fazio V, Singhal SS, Cucullo L, Awasthi YC, Dini G, Janigro D. RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci 2005; 6: 61.
128. Sharma R, Awasthi YC, Yang Y, Sharma A, Singhal SS, Awasthi S. Energy dependent transport of xenobiotics and its relevance to multidrug resistance. Curr Cancer Drug Targets 2003; 3(2): 89-107.
129. Soranzo N, Kelly L, Martinian L, Burley MW, Thom M, Sali A, Kroetz DL, Goldstein DB, Sisodiya SM. Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy. Epilepsia 2007; 48: 674-683.
130. Leschziner GD, Jorgensen AL, Andrew T, Williamson PR, Marson AG, Coffey AJ, Middleditch C, Balding DJ, Rogers J, Bentley DR, Chadwick D, Johnson MR, Pirmohamed M. The association between polymorphisms in RLIP76 and drug response in epilepsy. Pharmacogenomics 2007; 8(12): 1715-1722.
131. Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiaty 2005; 57(11): 1239-1247.
132. Zhu G, Okada M, Yoshida S, Ueno S, Mori F, Takahara T, Saito R, Miura Y, Kishi A, Tomiyama M, Sato A, Kojima T, Fukuma G, Wakabayashi K, Hase K, Ohno H, Kijima H, Takano Y, Mitsudome A, Kaneko S, Hirose S. Rats harboring S284L Chnra4 mutation show attenuation of synaptic and extrasynaptic GABAergic transmission and exhibit the nocturnal frontal lobe epilepsy phenotype. J Neuroscience 2008; 28(47): 12465-12476.
133. Sugawara T, Saruwatari J, Yoshida S, Kanai K, Yoshida S, Wada K, Shimizu T, Nakagawa K, Hirose S, Kaneko S, The Epilepsy Genetic Study Group Japan. Development of a Tool for Genetic Diagnosis of Epielpsies. The 43rd Congress of the Japan Epilepsy Society: Post Congress International Symposium on Pharmacogenomics in Epilepsy 2009; Abstract: P08.